In the News

WASHINGTON, D.C. – “I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The Global Alzheimer’s Platform Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its […]

Winners to be recognized at UsAgainstAlzheimer’s 2019 National Summit in Washington, D.C. WASHINGTON, D.C. (September 25, 2018) – More than 5.7 million Americans suffer from Alzheimer’s disease and researchers rely upon clinical trial volunteers to be the first step towards a cure. The Global Alzheimer’s Platform Foundation (GAP) has launched the Citizen Scientist Awards®, the first national awards program recognizing and celebrating Alzheimer’s disease clinical […]

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures. A new report from top researchers says the number of drugs advancing through clinical phase two and […]

Alzheimer’s clinical trial participants are getting a lift to their appointments at Raleigh Neurology Associates. The Global Alzheimer’s Platform Foundation, in partnership with Lyft, is providing transportation to participants in an Eli Lilly study testing a therapy to attack plaque in the brain characteristic of Alzheimer’s disease. Sean Walsh, director of clinical research at Raleigh Neurology Associates, says the new […]

Lyft drivers will transport clinical trial participants to and from GAP-Net research sites WASHINGTON, D.C. (Mar. 20, 2018) – The Global Alzheimer’s Platform Foundation has launched a partnership with Lyft to provide transportation for Alzheimer’s clinical trial participants to and from research sites. The partnership began on Feb. 20 with a pilot in California. Transportation will be available for participants and care partners who […]

WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial […]

Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than […]

Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life.  My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be […]

More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites Kansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. (November 1, 2017) – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone. […]

The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), […]

Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost Bipartisan Support is Good Newsfor 5.5 Million Americans Living with Alzheimer’s and their Caregivers WASHINGTON, D.C. (May 4, 2017) – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National […]

Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise […]

Pascale Witz brings two decades of healthcare leadership experience to GAP Board WASHINGTON, D.C. (Sep. 15, 2016) – Global Alzheimer’s Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will provide counsel based […]

A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the […]

First?of?its?Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials WASHINGTON, D.C. (July 28, 2016) – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP?Net, a first?of?its?kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP?Net currently has 11 leading academic and private commercial […]

Dr. Zhong Brings More Than 20 Years of Experience to Organization’s New Role WASHINGTON, D.C. (July 27, 2016) – Global Alzheimer’s Platform Foundation (GAP), a nonprofit organization dedicated to reducing the time, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Dr. Kate Zhong to the new position of Chief Strategy Officer (CSO). In this […]

Global Alzheimer’s Platform (GAP) Foundation is promoting innovative and easier?to?use clinical trial participation tools, including the Brain Health Registry WASHINGTON, D.C. (July 18, 2016) – In a first?ever poll conducted online by Harris Poll on behalf of the Global Alzheimer’s Platform (GAP) Foundation, nearly 60% of Americans report they are definitely willing or would consider participating […]